id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-D-0861-0009,FDA,FDA-2021-D-0861,Cover Letter Attachments for Controlled Correspondence and Abbreviated New Drug Application Submissions; Guidance for Industry; Availability,Notice,Notice of Availability,2023-06-06T04:00:00Z,2023,6,2023-06-06T04:00:00Z,,2023-06-06T13:58:40Z,2023-11943,0,0,0900006485ac468b
FDA-2021-D-0861-0010,FDA,FDA-2021-D-0861,Cover Letter Attachments for Controlled Correspondence and ANDA Submissions Guidance for Industry,Other,Guidance,2023-06-05T04:00:00Z,2023,6,2023-06-06T04:00:00Z,,2024-11-12T05:49:54Z,,1,0,0900006485ac5eb7
FDA-2021-D-0861-0002,FDA,FDA-2021-D-0861,Cover Letter Attachments for Controlled Correspondences and Abbreviated New Drug Application Submissions; Draft Guidance for Industry; Availability,Other,Guidance,2021-12-13T05:00:00Z,2021,12,2021-12-13T05:00:00Z,2022-02-12T04:59:59Z,2023-06-06T14:10:09Z,,0,0,0900006484ec140c
FDA-2021-D-0861-0001,FDA,FDA-2021-D-0861,Cover Letter Attachments for Controlled Correspondences and Abbreviated New Drug Application Submissions; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2021-12-13T05:00:00Z,2021,12,2021-12-13T05:00:00Z,,2021-12-13T14:27:05Z,2021-26893,0,0,0900006484ec08ed